Skip to main content
. 2014 Nov 10;10(2):421–432. doi: 10.1021/cb500828m

Figure 9.

Figure 9

Screening of unique structural PLD inhibitors against (A) bacterial PldA and (B) mammalian NAPE-PLD. Compounds were screened against NAPE-PLD via a mass spectrometry assay at 20 μM, except for MAFP, which was used at 500 μM. PldA was screened using the exogenous assay at 20 μM. (C) Full CRC for 17b on mammalian NAPE-PLD (IC50 = 67 μM).